Braidwell LP Takes $9.09 Million Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Braidwell LP purchased a new position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 483,300 shares of the company’s stock, valued at approximately $9,091,000. Braidwell LP owned approximately 3.20% of Jasper Therapeutics as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in JSPR. Virtu Financial LLC purchased a new position in shares of Jasper Therapeutics during the 1st quarter worth approximately $306,000. Bank of New York Mellon Corp purchased a new position in Jasper Therapeutics in the second quarter worth $740,000. Rhumbline Advisers purchased a new position in Jasper Therapeutics in the second quarter worth $300,000. American Century Companies Inc. lifted its holdings in Jasper Therapeutics by 27.1% in the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock valued at $322,000 after acquiring an additional 3,032 shares during the period. Finally, Wolff Wiese Magana LLC acquired a new position in shares of Jasper Therapeutics during the 3rd quarter worth $59,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Stock Performance

Shares of NASDAQ:JSPR opened at $23.24 on Friday. The business’s fifty day moving average price is $20.26 and its two-hundred day moving average price is $20.90. The stock has a market cap of $348.60 million, a PE ratio of -4.90 and a beta of 2.19. Jasper Therapeutics, Inc. has a one year low of $4.00 and a one year high of $31.01.

Analyst Ratings Changes

Several analysts recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, October 24th. Royal Bank of Canada decreased their price target on Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 14th. Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. JMP Securities reaffirmed a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a report on Tuesday, October 15th. Finally, Evercore ISI reissued an “outperform” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a report on Monday, August 26th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $74.86.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.